The global veterinary vaccines market size was valued at USD 10.67 billion in 2025 and is projected to grow from USD 11.53 billion in 2026 to USD 21.49 billion by 2034, registering a CAGR of 8.09% during the forecast period from 2026 to 2034. North America dominated the veterinary vaccines market with a market share of 38.4% in 2025.
Veterinary vaccines are biological preparations developed to protect animals from infectious diseases by stimulating their immune systems to recognize and fight specific pathogens. They contain weakened, inactivated, or purified forms of disease-causing organisms or their components, enabling animals to build immunity without developing the disease. Veterinary vaccines are used in livestock, poultry, companion animals, and wildlife to prevent disease outbreaks, improve animal health and welfare, reduce the spread of infections, and support sustainable animal production and public health.
Download a Free Sample To learn more about this report,
Expansion of Vaccines for Emerging and Transboundary Animal Diseases
Veterinary vaccine development is increasingly responding to diseases that can cause major livestock losses and disrupt animal movement and trade. Research organizations and manufacturers are working on vaccines for diseases where existing control measures remain limited, creating new product opportunities for livestock health and disease preparedness. This is broadening the veterinary vaccine pipeline beyond established vaccination programs.
In April 2026, ICAR transferred technology for an indigenous live-attenuated lumpy skin disease vaccine to Brilliant Bio Pharma in India. The technology was developed for cattle and was intended to support large-scale production and wider distribution of the vaccine across the livestock sector.
Development of New Generation Veterinary Vaccines
The veterinary vaccine industry is expanding beyond conventional vaccine technologies as manufacturers introduce products using recombinant, subunit, and other advanced approaches. These technologies can be designed for specific pathogens and may offer advantages in safety, targeting, or disease-control strategies. The emergence of new vaccine platforms is creating greater technological diversity within the veterinary vaccines market.
In 2025, the European Medicines Agency listed several new veterinary vaccines, including a vaccine against Brachyspira hyodysenteriae infections in pigs and a recombinant-protein vaccine against bluetongue virus serotype 3. The approvals demonstrate continued development of vaccines for different livestock species and disease targets.
Expansion of Livestock Disease-Control Programs Supports Vaccine Consumption
Government disease-control programs create direct demand for veterinary vaccines because vaccination is used to reduce disease prevalence, protect livestock populations, and limit economic losses from outbreaks. Organized vaccination campaigns can generate substantial requirements for vaccines when authorities target specific high-risk animal populations or geographic regions. This supports veterinary vaccines market demand beyond routine private-sector veterinary use.
In 2026, WOAH's Vaccine Bank mechanism supported the delivery of 1.15 million doses of peste des petits ruminants vaccine to Kenya under the PC-TAD project. The program also supplied cold-chain and vaccination equipment to support implementation in targeted high-risk counties.
Temperature-Sensitive Products Increase Distribution Requirements
Many veterinary vaccines require controlled storage and transportation conditions to maintain their effectiveness. Maintaining appropriate temperatures throughout transportation, storage, and administration requires specialized equipment, monitoring, trained personnel, and reliable logistics. These requirements can increase distribution costs and make vaccine delivery more difficult in areas where cold-chain infrastructure is limited.
In July 2025, the World Health Organization issued its seventh edition of international vaccine packaging and shipping guidelines, highlighting temperature control, quality checks, packaging requirements, and transportation conditions as important considerations in international vaccine shipments. Although the guidelines cover vaccines broadly, the logistics requirements are directly relevant to temperature-sensitive veterinary vaccine supply chains.
Commercialization of Locally Developed Veterinary Vaccine Technologies
Technology transfer from research institutions to private manufacturers is creating opportunities to expand domestic veterinary vaccine production. Local manufacturing can provide additional production capacity for diseases that have major regional livestock impacts and can reduce dependence on imported products. Partnerships between research institutions and pharmaceutical manufacturers can therefore accelerate commercialization and broaden vaccine availability.
In April 2026, ICAR commercialized its lumpy skin disease vaccine technology through a licensing agreement with Brilliant Bio Pharma. The agreement included a ₹75 lakh technology licensing fee plus a 5% royalty on sales and represented the sixth company to receive the technology.
Maintaining Vaccine Quality Through Procurement and Field Administration
Veterinary vaccine effectiveness depends not only on product development but also on appropriate procurement, quality assessment, storage, handling, and administration. Differences in veterinary infrastructure and implementation capacity can make it difficult to maintain consistent vaccination quality after products leave manufacturing facilities. This creates challenges for governments and veterinary services implementing large-scale disease-control programs.
In May 2025, WOAH's veterinary vaccine technical forum emphasized the need to strengthen vaccination systems through science-based policies, improved implementation, and better coordination between stakeholders. The organization linked effective vaccination with animal health, zoonotic-disease prevention, antimicrobial-use reduction, and broader One Health objectives.
Attenuated Live Vaccines Segment Dominated the Veterinary Vaccines Market with 34.2% Share in 2025
The attenuated live vaccines segment dominated the global veterinary vaccines market with a 34.2% share in 2025, driven by their ability to generate strong, long-lasting immune responses and provide effective protection against a wide range of infectious animal diseases. These vaccines are widely used in livestock and companion animals because they often require fewer doses while delivering durable immunity. WOAH recognizes live attenuated vaccines as an important tool in disease prevention and control when used under appropriate vaccination strategies and quality standards.
The inactivated vaccines segment continues to witness steady demand because of its strong safety profile and suitability for routine vaccination programs, particularly where live vaccines are not appropriate. The subunit vaccines segment is gaining attention for providing targeted immune responses with a reduced risk of adverse reactions, making them increasingly valuable in modern veterinary medicine.
The DNA vaccines segment is expanding as advances in biotechnology improve vaccine development and offer new approaches for controlling emerging animal diseases. The recombinant vaccines segment is also experiencing steady growth, supported by ongoing research into next-generation vaccines that enhance efficacy, improve safety, and enable more precise disease prevention across livestock and companion animals. WOAH recommends selecting vaccine technologies based on disease epidemiology, safety, efficacy, and vaccination objectives.
Request Customizationto receive a tailored report.
Aqua Segment is Projected to Register the Fastest Growth in the Veterinary Vaccines Market at a CAGR of 8.37%
The aqua segment is projected to register the fastest growth in the veterinary vaccines market at a CAGR of 8.37% during 2026–2034, driven by the rapid expansion of aquaculture and increasing efforts to prevent infectious diseases in farmed fish. WOAH identifies vaccination as one of the most cost-effective strategies for improving aquatic animal health, reducing disease outbreaks, and supporting sustainable seafood production. Growing investment in fish vaccination technologies and improved disease surveillance is expected to further strengthen this segment.
The poultry segment continues to account for the largest share of the veterinary vaccines market due to intensive commercial poultry production and the need to prevent highly contagious diseases that can significantly affect productivity and food security. The ruminant segment remains an important contributor as vaccination programs help improve herd health, productivity, and disease control in cattle, sheep, and goats.
The companion animals segment continues to expand with rising pet ownership, increasing expenditure on preventive veterinary care, and greater awareness of routine immunization. Veterinary authorities worldwide continue to emphasize systematic vaccination programs as an essential component of animal health management and zoonotic disease prevention.
Speak to an Analystto discuss market opportunities.
North America's veterinary vaccines market accounted for 38.4% of the global market, reaching USD 4.10 billion in 2025, and is projected to grow at a CAGR of 6.92% during the forecast period. The region's growth is driven by increasing pet ownership, rising livestock health management practices, growing awareness of zoonotic diseases, and strong investments in animal healthcare. Continuous advancements in veterinary biologics and supportive government vaccination programs further contribute to regional market expansion.
The US market was valued at approximately USD 3.57 billion in 2025, making it the largest market in North America. Rising demand for companion animal vaccines, expanding livestock vaccination programs, and increasing investments in veterinary research continue to drive market growth.
Canada's market reached approximately USD 0.53 billion in 2025. Growing awareness of animal disease prevention, expanding livestock production, and increasing expenditure on companion animal healthcare are contributing to steady market expansion.
Unlock Regional Insightsto access country-level data, & regional trends.
Europe veterinary vaccines market accounted for 27.6% of the global market, reaching USD 2.94 billion in 2025, and is expected to grow at a CAGR of 6.74% during the forecast period. The market is supported by stringent animal health regulations, rising demand for preventive veterinary care, expanding livestock farming, and increasing adoption of vaccination programs across companion and farm animals.
The UK market was valued at approximately USD 0.65 billion in 2025. Increasing pet adoption, growing awareness of preventive animal healthcare, and expanding veterinary services continue to support market growth.
Germany's market accounted for approximately USD 0.79 billion in 2025. The country's advanced veterinary healthcare system, strong livestock industry, and increasing focus on animal disease prevention continue to strengthen market expansion.
The Asia Pacific veterinary vaccines market accounted for 22.8% of the global market, valued at USD 2.43 billion in 2025, and is projected to register the fastest CAGR of 8.61% during the forecast period. Rising livestock production, increasing pet ownership, growing awareness of animal health, and expanding government vaccination initiatives continue to strengthen regional market growth. Increasing investments in veterinary healthcare infrastructure are also supporting market expansion.
Japan's market generated approximately USD 0.44 billion in 2025. Growing demand for companion animal healthcare, increasing adoption of preventive vaccination, and advancements in veterinary biotechnology continue to support market growth.
China's market accounted for approximately USD 1.41 billion in 2025, representing the largest share within Asia Pacific. Expanding livestock farming, increasing government support for animal disease control, rising pet ownership, and growing domestic vaccine production continue to drive market expansion.
The Middle East & Africa veterinary vaccines market accounted for 4.8% of the global market, totaling USD 0.51 billion in 2025, and is anticipated to grow at a CAGR of 6.35% during the forecast period. Increasing awareness of livestock disease prevention, expanding animal healthcare infrastructure, and rising investments in veterinary services continue to support regional market growth.
The UAE market was valued at approximately USD 0.11 billion in 2025. Growing investments in livestock health, increasing adoption of companion animals, and expanding veterinary healthcare facilities continue to support market development.
Africa's market reached approximately USD 0.40 billion in 2025. Expanding livestock production, increasing government vaccination programs, improving access to veterinary services, and growing awareness of animal health management continue to create long-term growth opportunities across the region.
Customize This Report to Match Your Strategic Objectives
Author's Details
Senior Research Associate
Dhanshee Bhapkar is a healthcare research professional with 4+ years of experience in market intelligence, specializing in market analysis, secondary research, market estimation, and forecasting across the pharmaceutical, biopharmaceutical, and medical device sectors. She provides actionable insights into market dynamics, competitive intelligence, industry trends, and growth opportunities to support strategic business decision-making.
Her expertise includes assessing market size, growth potential, and revenue opportunities through structured market estimation and forecasting methodologies, including top-down, bottom-up, and epidemiology (EPI)-based approaches. She has hands-on experience analyzing disease epidemiology, treatment landscapes, market trends, competitive scenarios, and industry developments to develop robust market forecasts.
Veterinary Point of Care Diagnostics Market Size, Share, 2034
Pet Care Market Size, Share, Growth, Analysis, Report, 2034
Farm Animal Healthcare Market Size, Share, Growth, Analysis, 2034
Veterinary Pharmaceutical Drugs Market Size, Share, Growth, 2034
Veterinary Dermatology Drugs Market Size, Share, Growth, 2034
Veterinary Rehabilitation Services Market Size, Share, Growth, 2034
We are featured on:
sales@straitsresearch.com